ReviewDrug safety2025

Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC): A Quantitative Review of the Post-Authorisation Safety Evaluation of Antidiabetic Drugs from 2012 to 2022.

Haoxin Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.